Correlation of immunohistochemical expression of p53 with unamplified chromosome 17 polysomy in invasive breast carcinoma

Applied Immunohistochemistry and Molecular Morphology

Volumn 19, Issue 1, 2011, Pages 28-32

  Krishnamurti, Uma ^a   Zarineh, Alireza ^b   Atem, Folefac D ^c   Silverman, Jan F ^a,b  

^a WESTERN PENNSYLVANIA HOSPITAL   (United States)

^b ALLEGHENY GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

breast carcinoma; P53; polysomy 17

Indexed keywords

ESTROGEN RECEPTOR; PROTEIN P53;

ARTICLE; BREAST CARCINOMA; CHROMOSOME 17; CHROMOSOME 17 POLYSOMY; CHROMOSOME STRUCTURE; CONTROLLED STUDY; CORRELATIONAL STUDY; GENE AMPLIFICATION; HEAD AND NECK CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

ANEUPLOIDY; BREAST NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM INVASIVENESS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 78650821144     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3181e9bb6f     Document Type: Article

References (38)

1. Isobe M, Emanuel BS, Givol D, et al. Localization of gene for human p53 tumour antigen to band 17p13. Nature. 1986;320:84-85.
2. Matlashewski G, Lamb P, Pim D, et al. Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene. EMBO J. 1984;3:3257-3262.
3. Kern SE, Kinzler KW, Bruskin A, et al. Identification of p53 as a sequence-specific DNA-binding protein. Science. 1991;252:1708-1711.
4. Marx J. How p53 suppresses cell growth. Science. 1993;262:1644-1645.
5. Ziemer MA, Mason A, Carlson DM. Cell-free translations of proline-rich protein mRNAs. J Biol Chem. 1982;257:11176-11180.
6. Baker SJ, Fearon ER, Nigro JM, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science. 1989; 244:217-221.
7. Cheng J, Haas M. Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines. Mol Cell Biol. 1990;10: 5502-5509.
8. Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature. 1989;342:705-708.
9. Sasano H, Goukon Y, Nishihira T, et al. In situ hybridization and immunohistochemistry of p53 tumor suppressor gene in human esophageal carcinoma. Am J Pathol. 1992;141:545-550.
10. Banks L, Matlashewski G, Crawford L. Isolation of human-p53- specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem. 1986;159:529-534.
11. Kerns BJ, Jordan PA, Moore MB, et al. p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. J Histochem Cytochem. 1992;40:1047-1051.
12. Kaserer K, Schmaus J, Bethge U, et al. Staining patterns of p53 immunohistochemistry and their biological significance in colorectal cancer. J Pathol. 2000;190:450-456.
13. Esrig D, Spruck CH III, Nichols PW, et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol. 1993;143:1389-1397.
14. Borre M, Stausbol-Gron B, Overgaard J. p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting. J Urol. 2000;164:716-721.
15. Ilmonen S, Hernberg M, Pyrhonen S, et al. Ki-67, Bcl-2 and p53 expression in primary and metastatic melanoma. Melanoma Res. 2005;15:375-381.
16. Pricolo VE, Finkelstein SD, Hansen K, et al. Mutated p53 gene is an independent adverse predictor of survival in colon carcinoma. Arch Surg. 1997;132:371-374; discussion 374-375.
17. Blaszyk H, Hartmann A, Cunningham JM, et al. A prospective trial of midwest breast cancer patients: a p53 gene mutation is the most important predictor of adverse outcome. Int J Cancer. 2000;89:32-38.
18. Kovach JS, Hartmann A, Blaszyk H, et al. Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc Natl Acad Sci USA. 1996;93:1093-1096.
19. Pietilainen T, Lipponen P, Aaltomaa S, et al. Expression of p53 protein has no independent prognostic value in breast cancer. J Pathol. 1995;177:225-232.
20. Reed W, Hannisdal E, Boehler PJ, et al. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years. Cancer. 2000;88:804-813.
21. Thor AD, Yandell DW. Prognostic significance of p53 overexpression in node-negative breast carcinoma: preliminary studies support cautious optimism. J Natl Cancer Inst. 1993;85:176-177.
22. Torrisi R, Rotmensz N, Bagnardi V, et al. HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17. Eur J Cancer. 2007;43:2339-2344.
23. Takehisa M, Sasa M, Bando Y, et al. Chromosomal aneusomy (chr 1, 11, 17) detected by fluorescence in situ hybridization may be a prognostic factor in breast cancer. Anticancer Res. 2007;27: 1073-1078.
24. Hyun CL, Lee HE, Kim KS, et al. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer. J Clin Pathol. 2008; 61:317-321.
25. Tsukamoto F, Miyoshi Y, Egawa C, et al. Clinicopathologic analysis of breast carcinoma with chromosomal aneusomy detected by fluorescence in situ hybridization. Cancer. 2001;93:165-170.
26. Kawai T, Hiroi S, Nakanishi K, et al. Abnormalities in chromosome 17 and p53 in lung carcinoma cells detected by fluorescence in situ hybridization. Pathol Int. 2004;54:413-419.
27. Simonetti S, Russo R, Ciancia G, et al. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17. Int J Surg Pathol. 2009;17:198-205.
28. Charuruks N, Shin DM, Voravud N, et al. Genetic instability and the development of recurrence of primary tumor and second primary tumor during head and neck tumorigenesis. J Med Assoc Thai. 1996;79 (Suppl 1):S49-S55.
29. Shin DM, Charuruks N, Lippman SM, et al. p53 protein accumulation and genomic instability in head and neck multistep tumorigenesis. Cancer Epidemiol Biomarkers Prev. 2001;10: 603-609.
30. Krishnamurti U, Hammers JL, Atem FD, et al. Poor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinoma. Mod Pathol. 2009;22:1044-1048.
31. Hofmann M, Stoss O, Gaiser T, et al. Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy. J Clin Pathol. 2008;61:89-94.
32. Salido M, Tusquets I, Corominas JM, et al. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry. Breast Cancer Res. 2005; 7:R267-R273.
33. Varshney D, Zhou YY, Geller SA, et al. Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay. Am J Clin Pathol. 2004;121:70-77.
34. Douglas-Jones AG, Collett N, Morgan JM, et al. Comparison of core oestrogen receptor (ER) assay with excised tumour: intratumoral distribution of ER in breast carcinoma. J Clin Pathol. 2001; 54:951-955.
35. Li X, Tsuji T, Wen S, et al. Detection of numeric abnormalities of chromosome 17 and p53 deletions by fluorescence in situ hybridization in pleomorphic adenomas and carcinomas in pleomorphic adenoma. Correlation with p53 expression. Cancer. 1997;79: 2314-2319.
36. Li B, Kanamaru H, Noriki S, et al. Numeric aberration of chromosome 17 is strongly correlated with p53 overexpression, tumor proliferation and histopathology in human bladder cancer. Int J Urol. 1998;5:317-323.
37. Kanekawa A, Tsuji T, Oga A, et al. Chromosome 17 abnormalities in squamous cell carcinoma of the oral cavity, and its relationship with p53 and Bcl-2 expression. Anticancer Res. 1999;19: 81-86.
38. Marchio C, Lambros MB, Gugliotta P, et al. Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol. 2009;219:16-24.